Seeing the severe damage brought about by African Swine Fever locally and even globally, not only in terms of economic losses but also on animal health and welfare, solutions offered to provide a possible remedy must be encouraged and evaluated.

 

ASF vaccine development is in the forefront of these efforts. Many researches have been conducted to find a suitable vaccine using different approaches, from using whole inactivated viruses, use of naturally attenuated strains, recombinant viral vectors or DNA or RNA vaccines.

 

Recent peer reviewed technical papers on modified live virus (MLV) gene-deleted ASF vaccines point out to their efficacy and safety; and at the moment, the best choice for an ASF vaccine format.

 

An MLV gene deleted vaccine candidate has now passed government evaluations and have received a Certificate of Product Registration under Monitored Release (CPR MR). The vaccine has undergone safety and efficacy tests and has shown results that it will be beneficial for the industry to have this vaccine as a tool to prevent and control ASF outbreaks.

 

PCSP, considering the risks and to help further evaluate benefits of the use of a Modified Live Vaccine for ASF, supports government efforts to distribute the vaccine via controlled monitored release with the set condition of usage/consumption and disease update reports from beneficiaries and buyers.

 

While there is noted initial success on its use on finishers, its label certifies that it is not for use in sows, usage should be restricted to label recommendations.

 

Farms are encouraged to consult veterinarian to determine the health status of animals prior to vaccination.